According to the research abstract released on the society's homepage on the 14th local time, the company plans to present data on the anti-tumor efficacy of BBT-207 as well as its ability to inhibit brain metastases confirmed through the results of preclinical studies that have progressed over the past year.
BBT-207 is the first new drug candidate independently discovered by
The company presented preclinical data of BBT-207 in the form of a poster at the AACR held last year, revealing the pharmacokinetic properties of the drug explored based on cell lines and animal experiments, as well as inhibition of C797S-positive double mutations and various resistance mutations. there is. At this conference, based on the results of additional animal experiments, anti-tumor efficacy survival improvement in brain metastasis animal models, data related to brain metastasis inhibition, which examines the possibility of targeted treatment for C797S-positive mutations, are presented, and are expected to expand the treatment strategy currently in progress. The possibility of development as a 4th-generation non-small cell lung cancer targeted therapy that can respond to various mutations caused by the disease will be discussed.
Vice President
As Tagrisso expands its scope as a first-line treatment for non-small cell lung cancer, the need for new treatment options targeting various mutations, such as the C797S-positive double mutation, is increasing. BBT-207 is being developed as a fourth-generation treatment that can respond to various resistance mutations, including the C797S-positive double mutation, and is developing with the goal of submitting a clinical trial plan (IND) to the
Meanwhile,
(C) 2023 Electronic News Publishing, source